Names that move as a basket.

Beat-and-raise sold hard: $430.16 on 08-05 to $317.93 on 08-07, -26.1% in two sessions on the window's heaviest volume, while four brokers raised targets to $449–$490 on 08-06. Growth intact (FY26 guide up to $725–735M, adj EPS…

AI-server order book unchanged since the 2026-05-28 print ($51.3B backlog, ~$60B FY27 AI-server guide) while price added 26.4% in four sessions to a $467.27 close on 2026-08-04 — a new high built on cohort beta and Micron-driven sentiment,…

Relief bounce off the broker-liability selloff stalled: LSTR closed $183.09 on 2026-08-07 after $181.62 on 08-04, below the 50-day at $205.13 and above a rising 200-day at $166.56. DAT dry van and flatbed have fallen two straight weeks to…

Custom-silicon ASIC royalty story intact, but the AI-semi theme is mid-correction — chips posted their worst month vs software on record (7/17) with money rotating into energy. Buying a falling sector with no confirmed higher low is the…

Record made 2026-08-04 ($190.46 close, $195.70 intraday) has held — 2026-08-07 closed $189.52 with no give-back. Second tuck-in in three weeks (JetStream, 2026-08-06, undisclosed). No Q1 FY27 webcast notice as of 2026-08-09, which argues…

The 2026-08-04 breakout above the July band failed within three sessions — SNX closed $252.42 on 2026-08-07, back inside the $235.67–$255.70 range and under the 50-day. The move up came on Arista's print, not company news; Hyve's +117%…

Maturing AI-storage supercycle with sell-side still chasing: Wells Fargo upgrade to Overweight $1,100 (7/10) and Citi Street-high $1,240 (7/13). But the DRAM ETF is down ~30% and Seagate's Q4 FY26 print ~2026-07-22 is a binary about two…

Silicon-photonics pivot re-rated the ADR ~3x, but the July blowoff to $28.96 round-tripped -26% to $21.25 in days while sell-side finally upgraded (Macquarie Outperform 2026-07-14) — late-stage distribution behaviour. The 2026-07-29 Q2…

The 29% bounce off the 2026-07-28 low stalled: WDC closed $527.22 on 2026-08-03, −3.23% on a day its sector rose 0.58%, back under a rising 50-day at $562.65. Consensus (~$3.69B / $3.31–$3.35) still sits above the company's own $3.65B…

Q2 delivered into the 2026-08-04 FCC policy gap: revenue $191.9M (+86% YoY), first non-GAAP profit at $0.06 vs $0.01 consensus, capacity sold out through mid-2027. But the Q3 EPS guide of $0.11–$0.26 tops out under the $0.28 consensus,…

Order cadence is intact — 2026-06-17, 07-09, 08-04 — but the 2026-08-04 spike to $109.89 has bled to $103.07 (2026-08-07 close) with no company disclosure since. The second distinct hyperscaler AI-ASIC order that the $130–150M FY2027 guide…

Float-royalty leg is finished; the stock now trades on Arc. Q2 (2026-08-05) printed $73.3B USDC circulation and $701.3M revenue vs $718.6M consensus, but FY26 other-revenue guidance doubled to $310–330M and Arc mainnet targets 2026-09-16…

Neocloud re-rate has fully round-tripped: $33.62 close 7/17, -42% in 30 days, late-May Microsoft breakout base surrendered. Contracts intact ($9.7B MSFT, prepaid tranches) but Q3 AI revenue was only $17.3M vs a $3.4B ARR ambition, and…

The AI-memory leg MTUM rotated into at the May reconstitution has rolled over: SOX -20%+ from its June peak, memory names in a bear market, and the fund closed $302.09 on 2026-07-17, below the $310 shelf that defined the…

Three straight cohort-driven sessions carried OKLO from the 2026-07-29 close of $36.84 to $43.33 on 2026-08-04, with no Oklo release behind any of them. The 2026-08-07 Q2 call is the binary.

Legacy crypto-financials name re-rating to AI-data-center landlord: Phase I ~200MW at the Helios campus was delivered to CoreWeave on 2026-07-06, turning the ~$4.5B/15-yr lease from promise into live contracted revenue while shares still…

Bitcoin-miner-to-AI-datacenter-landlord re-rate is now financed fact ($4.25B IG notes 6/4, ~$16.8B contracted backlog), but the momentum leg rolled from ~$127 to ~$105 as peers WULF/IREN captured the marquee Anthropic tenant deals (7/6)…

The WFE/AI-memory capex trade that ran Lam +119% YTD into June has rolled into a group-wide correction — the worst month for chip stocks since 2008, memory momentum broken (Micron/SanDisk). The ~2026-07-29 FQ4 print is now the binary: it…

June breakout fully round-tripped: ATH $386.46 (6/30) to $279.85 (7/17), now below the 50-DMA at $294.49. The tell is non-participation — TSMC raised capex to $60-64B and ASML guided up twice on 7/15-16, and ONTO closed the week at its…

The data-center re-rating already failed: QCOM spiked to a 52-week high of $259.92 on the ~2026-06-24 Investor Day $15B-by-2029 guide, then gave back ~34% in 17 sessions to $171.78 as Hold downgrades and Apple modem-attrition math…

BTC-to-AI-landlord re-rating is structurally intact — AMD $311M/50MW Rockdale lease, $33.2M Q1 data-center revenue, Citi reiterated Buy/PT $28 on 2026-07-08 — but the miner complex rolled over on a Q2 crypto rout and "fresh AI-pivot…

Solar/BESS EBOS name re-rated as a 2nd-order AI-datacenter-power play on a record $758M Q1 backlog and the multi-GW ON.energy deal; price reclaimed the $10 pivot but consensus PT sits at spot (~$10.63 vs $10.02), so the confirmed…

Conway extract/RTD/flavors platform inflecting capex-to-cash: Q1 (5/07) beat + record adj EBITDA + FCF-positive-H2 guide; the 6/30 debt-maturity extension cleared the refi wall. Stock re-rated to ~$9.50 near the $9.81 52-wk high. Q2…

BASX data-center cooling re-rating is intact but the setup for a fresh buyer today is poor: four days from a binary Q2 print (2026-07-30, inside blackout), KeyBanc just initiated at neutral (Sector Weight, 2026-07-23), ~55x forward with…

Second-leg breakout failed: after tagging a 52-week high $8.44 in early July, ABCL round-tripped to $5.31 (2026-07-24, -6.35%), losing the $6.79 shelf and $6.20 retest line, back at the June ~$5.09 base. The momentum edge is gone; what's…

Post-crash re-rating leg: the 2026-06-18 FY26 guide cut took ACN -17.9% in a day to a $118.15 low, then a $7.5B buyback (+62% YoY, must complete by 2026-08-31) plus named AI wins (Google Cloud, NATO, UniCredit) drove +24.8% in four…

Frac-sand legacy pivoting to behind-the-meter gas power for AI data centers, but the story is DORMANT and the structure broken: shares fell from $16.73 (6/29) to an $11.96 close (7/24, -8.5%), losing the ~$15 base and $13 shelf on…

AI-data-center gas-EPC theme still ACCELERATING (4.1+ GW gas backlog, $973.6M cash, zero debt), but AGX has round-tripped from the $805.75 ATH to $563, losing both the ~$675 breakout and ~$600 shelves. Mean reversion toward the pre-run…

AI-agent-security theme is accelerating, but AKAM's July 8 re-firing (+8–10% toward $126) has fully faded to ~$115, rolling back toward the June lows — a legacy-CDN-to-security/compute pivot that is NOT confirming the theme's momentum. The…

AI rack-connectivity leader caught in a cohort-wide de-rate: down ~42% from the late-June $499 ATH as semis log their worst month versus software and the "is the AI trade cracking" question takes over. The $300 June recovery base is gone,…

The June AI data-center power-attach re-rate has flipped from being marked up to marked down: TD Cowen cut its target to $66 (2026-07-13) and Barclays downgraded to Equal-Weight at $48 (2026-07-20), the first target below the June range —…

WFE toll-collector on the AI-silicon buildout. June's +54% parabola — the most overbought reading in its history — corrected in July's semiconductor selloff that validated Burry's short. Now a pullback-to-base test: the June breakout base…

Professional-services roll-up re-rating: from a $16.00 IPO on 2025-12-17 to a $47.33 close on 2026-07-31, powered by the 2026-05-12 guidance raise to $980M–$1.0B FY2026 revenue. Price is discovered on a 10.90M-share float with a fifth to a…

Post-parabola digestion. The Apr–May "second-order AI power-semi" re-rate (~3x to $54.34) is fully priced, above the $30.50 consensus PT with no fresh company catalyst in 11+ weeks; the 2026-07-15 pop was a newsletter-driven volume spike,…

Advanced-packaging pricing power is real — quotes raised 20%+ (2026-07-01), 2026 capex hiked to US$8.5B, CoWoS-equivalent capacity tripling to 25k wpm — but the tape topped at $45.51 the same day and sits ~15% lower inside a 13% semi…

AI-security re-rate off the 2026-06-15 TrojAI deal has stalled: ATEN churning ~$35 below the $37.36 ATH, momentum cooling as Mizuho lifts its target to $34 but stays Neutral — analyst catch-up, not fresh conviction. The 2026-08-05 Q2 print…

AI test-intensity picks-and-shovels leader, but the narrative is MATURING: back-to-back upstream capex raises (TSMC $60–64B, ASML €43–45B) failed to lift the tape, and the ADR sits ~20% off its 2026-06-25 record, shedding another 6% on…

Beat-and-raise fired 2026-07-08 — Q1 adj EPS $1.85 vs $1.69, FY27 guide lifted twice on Metal Coatings momentum — but the catalyst is now behind the stock, which sits at all-time highs (~$157), ~23x forward and above consensus, with Wells…

Tape flipped since early July: BBY broke to a fresh 52-week high $87.35 (~$85.41 on 2026-07-17, +27.6% YTD) on RGB-LED TV exclusivity plus an AI-PC/MacBook refresh cycle. But price sits ~8% above the $79.15 consensus target while Loop…

On-site SOFC power for AI datacenters stays ACCELERATING and cluster-confirmed — Oaktree/IDF's $1.7B project financing (7/16) blunts the July supply-wall short thesis and JPM lifted its target to $346 (7/21) — but the ~2026-07-30 Q2 print…

Both legs of the wrapper are now rolling over: WhiteFiber (WYFI, ~70.5% owned) de-rated from $38.50 to $27.57 as the June neocloud mania cooled, and BTBT slid to ~$1.50, a step above its $1.25 low. SOTP discount still ~49% (~$745.6M WYFI…

Spring miner-to-AI re-rate has fully unwound: BTDR lost the $15 shelf to $12.56 (2026-07-09) as AI-cloud ARR plateaued at ~$69M for a 2nd month. A signed-but-not-effective Tydal colocation lease (2026-06-29) and a $36M Nevada plant are the…

Post-blowoff digestion is deepening: the ~4x data-center site-work roll-up has bled from a $96 high back to its $63 average analyst target, now below the $73 secondary price and the 50-DMA. Q1 organic +64% and an $854M backlog keep…

Second-order AI-server reseller whose ~37% recovery off the $97 low has stalled: a mid-July push to $144 round-tripped to $133 by 2026-07-17, right in the fairway of the ~$145 consensus target. The re-rate (JPM, MS $170, Citi $145) is…

2nd-order AI-power name — Q1 orders +97% YoY and a first-ever >$1B backlog (2026-04-28) feed the datacenter/electrification capex wave, and the closed Thermon merger doubled EBITDA. But price rolled over ~25% off the $101.24 ATH to $75.63,…

AI-datacenter EMS picks-and-shovels story still fundamentally climbing after the 2026-04-27 Q1 crush (rev +53% to $4.05B, FY26 guide raised to $19B), but the tape broke ~21% off its $474 June high and heads into a binary 2026-07-27 Q2…

Legacy-networker AI re-rate intact and now at its binary: the $118–120 shelf held through July, price closed $121.43 on 2026-08-07 with RSI(14) at 78.4, and five sell-side target raises landed 07-22 → 08-06 (Citi $112→$139) ahead of the Q4…

Legacy IT-services name being re-underwritten as an enterprise-AI deployment partner: 2026-07-29 Q2 lifted FY26 adj EPS guidance to $5.70–$5.82 and expanded margin 40bps while cutting the FY revenue band to $22.04–$22.35B. The re-rating is…

The AI-server/auto power-content re-rate that carried DIOD to a ~$126 all-time high (June 18) has round-tripped: a double-top, an analyst downgrade, more insider selling and a sector-wide semi selloff pushed it to ~$96 by July 10, through…

Fundamentals accelerated on the 2026-08-04 Q2 print (revenue +29% YoY, AI ARR +212%, RPO $894M, FY guide raised) and the stock fell 10.9% anyway. The $132 shelf flagged in the July coverage broke; the 2026-08-07 close is $124.15, -31.5%…

The pivot is now structural: the rail subsidiary was sold 2026-08-05 (related party — interim CFO owns 50% of the buyer), leaving an edge-colocation operator carrying a 2026-07-16 five-year 10 MW hyperscaler contract worth >$111M. The tape…

Legacy IT-services decliner being re-rated as an AI-centric pivot: AI-framed leadership change 2026-07-30, ElevenLabs and Primary partnerships inside ten days, FY27 non-GAAP EPS guide of $2.40–$2.90 affirmed against a $10.84 close.…

Scarcity-premium narrative is dead: DXYZ closed $22.51 on 2026-07-28, below its last reported $24.56 NAV (2026-03-31), then bounced to $25.89 on 2026-08-07 as SPCX absorbed its 911.5M-share 2026-08-06 unlock. What trades now is a near-NAV…

Legacy IT-services base re-rating on an AI-delivery pivot: the 2026-07-29 Q2 beat (adj EPS $0.91 vs $0.82) plus a $115M Army DEVCOM AI award drove +16.3% on 2026-07-30. Revenue is still -1.3% YoY, RSI(14) hit 94.5 at the 2026-08-07 close…

IQ SST AI-data-center pivot (announced 2026-04-28) that drove a spring squeeze has stalled — stock de-rated ~16% in a month to ~$45 (2026-07-09), sell-side uniformly neutral with PTs on top of price (Susquehanna $45, 2026-07-10), and SST…

AI-native revenue is compounding ($160M in Q2, >11% of total) but the task-based book is running off faster — FY26 organic constant-currency growth was cut to 2.0%–3.0% on 2026-08-06, Q3 guided to ~1.7% YoY, and the stock closed $97.43,…

Legacy campus-networking name re-rating ~+140% off Feb lows on the Platform ONE / Agent ONE AI-NetOps story plus SaaS ARR +29% YoY; theme still ACCELERATING but spot ($33.71, 07-10) has run through consensus PT $29.06 into the June bull…

Street targets re-rated up to the price rather than the reverse: average PT $22.83 across 8 analysts vs the 2026-08-07 close of $20.43, after B. Riley $13→$32 (6/29) and UBS $22→$27 (7/14). The AI-power bid still works (7/30 Microsoft…

AI-manufacturing re-acceleration: the 2026-07-09 Cerebras CS-3 production expansion is the first company-specific bid since the S&P-inclusion +6% pop round-tripped to ~$147, refreshing the data-center power/EMS narrative into the ~07-29 Q1…

Second secondary in five weeks — ~43.6M shares at $49 on July 2, now including company primary dilution — confirms the recurring-supply pattern and dragged the stock from its $65.56 June-4 ATH back to the offering line. The…

The capitulation-to-re-rate leg is broken: FSLR closed 2026-07-31 at $211.03 versus a May high of $313.75, under both the 50-DMA ($245.17) and 200-DMA ($234.23). A Q2 beat on 2026-07-30 (EPS $3.92 vs $2.86) bought two sessions and drew…

Agentic-operations pivot is compounding in the segment data — Advanced Technology Solutions +24.1% to $363M, FY guide raised to at least 25% on 2026-08-06 — but the 73% legacy book grew 1.9% and caps total growth near 7%. Shares fell ~3%…

Alternatives-manager re-rate stalled — GCMG printed a new $14.38 high on the 2026-07-13 Piper upgrade, then reversed ~15% to a $12.20 close into the 2026-08-06 Q2 binary. The AI-datacenter infra/private-credit fundraising thesis is intact…

June drawdown fully retraced — $23.01 close (2026-06-22) to $27.63 (2026-07-29), still short of the $27.76 shelf from 2026-06-01 — and it happened on no company news. The now-confirmed 2026-08-06 Q1 FY27 print is the first quarter with…

AI-native restructuring re-rate — up to 400 job cuts, FY26 EBITDA guide raised to $75–80M — plus a low-float, Russell-inclusion squeeze that popped GRPN +10% on 2026-07-16. But Q1 billings fell 1% YoY and sell-side sits at Sell: a maturing…

Legacy B2B data business attempting to re-rate as an AI go-to-market platform. Q2 (2026-08-05) beat and raised on 1.2% revenue growth, 89% NRR and a $650.5M goodwill impairment; the stock ran ~14% in two sessions to $4.18 (RSI 76.9), above…

Turbo cash-cow re-rated (~8–9x → ~18x) on a datacenter/industrial oil-free cooling narrative; the parabolic Feb→June leg (~$20→$36) is spent, shares faded ~11% to the 50-day near $32.30, and the ~late-July Q2 print is the first chance to…

BTC-miner→AI-compute re-rating has its first blue-chip proof — BUZZ HPC's $220M Bell/Cohere sovereign-AI GPU deal (~$70M ARR) on top of $35M contracted ARR — but the stock stalled ~$3.79 below its early-June highs as BTC bled ~45-50% off…

AI training-data pure-play with a still-accelerating fundamental story (Q1 rev +54%, 40%+ FY26 guide reaffirmed 06-17) but a fully broken chart: ~-51% from the June $125.14 ATH to ~$61, with the CEO filing a fresh 200k-share sale on 07-16…

Long-form streaming growth is broken in the reported numbers — Q1 2026 revenue -13% YoY and operating income flipped to a RMB228.4m loss — so what is left to buy is the micro-drama/overseas/AI-cost pivot, which has no disclosed revenue…

China AI-compute capacity story is intact on fundamentals — AI gross billing +90% YoY and past half of public-cloud revenue in Q1 (reported 2026-05-27) — but the price leg broke: -32.3% from the $18.21 high with RSI(14) back at 70.0. The…

Former Bitfarms miner→AI/HPC-datacenter pivot has rolled over: June's push to ~$6.14 into Citizens' $10 initiation retraced to a ~$4.975 ref by 07-06, losing the $5.00 convert shelf and drifting toward the $4.00–4.20 base. Still zero…

Cyclical staffing recovery is fully printed — Q1 returned to YoY growth, Q2 guided +~4% — but price ran ~24% in three weeks to a fresh all-time high near $58.6, ~38% above the $42.33 consensus PT, into the confirmed 2026-07-27 Q2 print. A…

AI-datacenter MEP/HVAC pick-and-shovel story still improving on fundamentals (record $5.38B backlog, FY guide raised to $4.1–4.3B), but the tape has decoupled: ~33% off the $102 May close high, LGN sliced the $76 breakout shelf and rolled…

AI/HPC power-buildout re-rate is the leg being bought — the 2026-07-09 HIF deal adds up to 2 GW in Texas, lifting potential capacity toward ~4.8 GW — but the golden-cross base fully round-tripped to ~$11.4 as analysts cut across the board…

AI-data-center re-rating leg is unwinding — round-tripped from the $105.91 May ATH to the ~$84 50-day EMA under an unrebutted J Capital short thesis and a 2026-07-13 TD Cowen PT cut to $90; only the cyclical MCU/industrial recovery (~93%…

Atlas re-acceleration (+29.4% YoY, record $117M seq add; Q1 FY27, 2026-05-28) is intact, but the +18.5% post-print breakout fully round-tripped from $444.72 to a $294.10 close as the AI-software theme sold on margin-timing fear. Sell-side…

Operating leg accelerating into a de-rating tape: Q2 (2026-08-05) beat at $1.248B revenue / $3.30 adj EPS, Q3 guide $1.310–1.390B tops the $1.243B Street, leverage down to 3.0x — and the stock still fell 4.49% on the print and sits 31.4%…

Contracted AI-datacenter cooling story (>$4B Airedale agreement through 2029, $165M prepayment) is fundamentally intact, but a failed $323.25 breakout has unwound ~29%, lost the $260 base, and the theme has cooled to maturing. The…

AI data-center power narrative still accelerating fundamentally (Enterprise Data ~2x YoY to $262.8M Q1; Q2 guide $890–910M, +35% YoY), but the tape bounced ~12% off the ~$1,200 shelf to ~$1,468 and now stalls at the 50-day into a binary…

AI optical-interconnect arms-dealer with fundamentals still accelerating (FY26 DC growth guide >60%, Q3 guide $331-339M) but a July-broken chart: ~36% off the $418.90 high to ~$267 on the semi selloff, Russell Value index removal, and…

AI optical/interconnect re-rating is intact — PTs $105–125 (Stifel/Northland/Benchmark, 2026-06-25) versus a stock that ran ~$70→~$96.60 into late June — but the name now sits ~5 days from a binary Q2 FY26 print (~2026-07-23), retail…

Legacy plastics maker re-rated ~2.4x on a "Focused Transformation" — MTS distribution arm in discontinued ops, capital concentrated behind Signature/MegaDeck composite matting (Infrastructure orders +130% YoY, Q1 adj EPS $0.44 vs $0.28).…

AI-networking legacy re-rate extending on a harder catalyst leg — first commercial AI-RAN platform with Nvidia (07-15) plus Taiwan Mobile, Orange Belgium and NestAI defense wins. Theme ACCELERATING, but the 2026-07-23 pre-open Q2 print is…

Legacy steel-pipe maker re-rated into a water-infrastructure + precast roll-up on a record $373M WTS backlog, an ~83% Q1 beat, and the Permalok RBJ field win. Narrative intact but the setup is extended — last near $148, ~35% above the…

Squeeze leg broke: +43% in four sessions to a $63.79 high, then management priced 3.62M shares at $55.22 (~8% discount) and closed ~$191.9M net on 2026-07-06. Price round-tripped to $37.04, under the 20- and 50-day and under the $49…

Private-credit-stress bottom trade: OCIC redemption requests fell to 18.8% of shares in Q2 from 21.9% in Q1 and FRE rose 9% YoY to $392.2M at the 2026-07-30 print, driving a ~25% bounce off the 2026-07-10 FT/UBS-exodus low. The re-rating…

Beaten-down bill-pay compounder: Q1 2026 revenue +30.2% YoY yet shares carved a $20.11 June 52-week low on margin-mix fear. Now ~40% off that low into a binary ~Aug-4 Q2 print — the read is a recovering base, not a chase.

Post-correction RAIN RFID recovery has extended to $138.37 (2026-07-17), holding the reclaimed $128 April gap-fill and pressing the $144.57 post-earnings high — but the entire near-term read is the 2026-07-29 Q2 print (guide $103–106M, EPS…

Recovery leg re-fired: $66.06 (2026-06-05) → $71.49 on 2026-07-15 (+5.9%) → $73.20, back within 3% of the $75.25 high and ~6% ABOVE the $68.80 consensus target. Wells Fargo's 2026-07-10 note flags June financing data accelerating into a Q2…

The +475% hydrogen-comeback squeeze has broken: the $3.12 Q1 gap and the 50-day both failed, price is ~$2.17 (-20% in 30d), and Susquehanna cut its target $3.75 → $2.50 on 2026-07-10. The June 30 NY Gateway close resolved as a restructure…

The 800VDC AI-power re-rate has cracked. POWI lost the $74–78 May breakout shelf in a -20% week to $70.45 (2026-07-17) and now sits below the $76.20 average target for the first time since spring. The GaN cohort broke with it — NVTS is…

White-collar staffing in secular decline: Q2 EPS collapsed to $0.26 (2026-07-23) as AI automation and a frozen hiring market gut permanent-placement demand. The >5% dividend yield reads as a value-trap signal rather than a floor. No…

The sell-the-news break is now confirmed: RUM lost the $6.46–$6.66 100/200-day shelf and closed $5.76 on 2026-07-17, -19% from the post-rebrand tape and within 25% of the $4.62 52-week low. Every moving average is overhead. The 2026-08-10…

Agentic-identity story intact and the post-earnings flush is basing: SAIL clawed from a $13.33 low (6/22) back to $15.68 (7/17), a higher low off the $10.30 bottom. Growth decelerated (ARR +26% vs +30%) and guidance was only affirmed, so…

Legacy-EMS AI re-rate (AMD/ZT Systems datacenter manufacturing) blew off to a $282.72 ATH then corrected ~16% off the highs; the est. ~2026-07-27 FQ3 print is now ~9 days out and is the binary — it tests whether FQ2's +102% YoY surge was…

The mania leg broke in July — the $6.33 shelf and the $4.97 range low both went — and the 2026-08-05 Q2 print handed the name a different story: revenue $15.9M (+259% YoY) vs $9.6M consensus, plus the first positive operating income and…

Online-styling turnaround printed a 5th straight growth quarter and first sequential client gain (Q3, 2026-06-10) with a raised FY guide, but the post-print pop has fully round-tripped to ~$3.58 (2026-07-24) onto the $3.50 shelf, a second…

MEMS-timing picks-and-shovels story is fundamentally intact — Q1 datacenter revenue +158% YoY to 67% of sales, Renesas timing deal closed July 1 — but the momentum leg has broken: ~$550 on July 18 is ~39% off the May 11 all-time-high close…

Korea AI-infra narrative is loud while the ADR bleeds: $46.00 (06-02) to $30.62 (07-17), and both the 15GW plan (07-05) and JPMorgan's Overweight upgrade (~07-16) failed to hold a bid. The story flipped from AIDC margin accretion to ₩140T…

Dilution leg has broken the story: the $7B raise cleared at $27.50 on June 11 and spot is $24.18, with a live $2B ATM as forward supply. DDR contract prices +32% QoQ crush a business guiding 8.2–8.4% gross margin. Falling knife under all…

AI-interconnect fundamentals still accelerating (Q1 FY27 data center +85% YoY, Needham reiterated Buy/$200 on 2026-07-13), but the price leg has broken: -22.7% in a month to ~$125, through the 20- and 50-day, ~30% off the $177.35 high.…

The June defense-MoU / SpaceX-proxy leg broke: the $14.33 close (2026-08-07) is under the lost $15–16 Diehl base and 43.8% off the $25.48 high. What is live now is smaller and dated — NOAA's $3M HyMS extension (08-04) and a $12.40M…

Contested special situation: a real June 8 Kalshi prediction-markets data lane sits under an unresolved Muddy Waters fraud allegation (20–40% illegal-operator revenue) plus an SDNY class action. Price has round-tripped to ~$14 as three…

The June AI-data-center re-rating has failed its retest: $62.06 on 2026-07-17 is -22% from the 2026-06-22 high of $79.82 and back under the early-June breakout base, with a $1.5B convertible overhang and a 7% selloff that ignored a BofA…

Picks-and-shovels contractor for the AI data-center buildout; fundamentals still fire (Q1 rev +92% to $825.7M, FY26 EPS guide $16.50–17.15, $6.5B backlog) but the June-4 blowoff has de-rated ~36% to ~$635 in a sector-wide E&C selloff. The…

Mix-shift re-rating: AI Services hit $66.1M (+25.8%) in Q2 CY2026 on 2026-08-05 — seventh straight quarter above 25% — and is guided above 30% YoY in Q4 on AV/robotics work, against a 25%-of-revenue Trust & Safety book the market assumes…

Deep-cyclical industrial staffer re-rated +140% off the $3.18 low on a staffing-demand recovery and a data-center/energy labor boom lifting PeopleReady +19% YoY. Still loss-making (Q1 net -$19.8M), margins compressed, and the…

The AI-datacenter-landlord re-rate has stalled: TH peaked at $20.85 and has given back ~21% to $16.36 (2026-07-17) as TDR Capital affiliates distribute shares in-kind to partners, losing the $17 secondary clearing shelf while Oppenheimer…

Contracted-floor re-rating has stopped paying: the 2026-08-05 Q2 raised FY26 Adj EBITDA guidance to $2,025–2,225M and PJM's 2028/29 auction cleared >10 GW at the $325/MW-day cap, yet the stock closed $347.71 on 2026-08-07, 22% below the…

Activist sum-of-the-parts special situation cooling: the board-control catalyst passed, TheFork sold to Amex for $700M, and BTIG's July 21 downgrade reframed Viator as a keeper rather than the next breakup piece — draining…

TTM's 2026 momentum leg is dead: the AI/defense PCB story that ran to a $206.66 close (2026-06-15) unwound ~36% to ~$131 on no company news, and the stock now sits on ~$130 gap-fill support heading into a binary 2026-08-05 Q2 print. The…

Q2 (2026-07-22) was a double beat — $5.46B revenue, +23% YoY, EPS $2.14 — with a raised Q3 guide, yet TXN faded from ~$294 to ~$280: good news couldn't hold the bid, the $331.51 ATH leg is spent and the binary print has passed. The…

Hyperscaler dark-fiber demand turned the post-Windstream deleveraging grind into a growth story (~$1.5B disclosed funnel, $68.7M of Q1 IRU revenue from one hyperscaler), but the June re-rate to ~$11 has stalled in a three-week range above…

Networking-optical test theme still accelerating and the laggard test-and-measurement sleeve is finally re-rating: Susquehanna lifted its target to $66 (2026-07-01) and the small-cap-over-hyperscaler rotation flagged 2026-06-29 favors…

The precision-components AI re-rate topped at $151.78 and has round-tripped ~32% to $103.89 (2026-07-17), now below the $116.05 50-DMA after a 2026-07-13 gap-down. The narrative leg is unwinding into the 2026-08-05 Q2 print — a broken…

Cyclical modular-space leasing recovery with a small data-center kicker and an activist/M&A floor, but range-bound and digesting: shares drifted to ~$26 under the $31.88 high after the 2026-06-27 Russell growth-index removal. The confirmed…

Dormant China micro-cap attempting a fresh re-ignition on stacked headlines — a $20M non-binding term sheet for 10% of crypto-perps platform Riverbit (2026-07-14) and a Guangzhou government AI-hub agreement (2026-07-15) — but a live $6.36M…

Post-gap recovery has extended to $5.73 (2026-08-07), +42.5% in three months, into the $6–$7 band where support broke — on no new fundamental datapoint since the 2026-06-02 Q1 FY2027 print. The answer-engine repositioning is still absent…

Zero-trust compounder trading at half its 52-week high after the 2026-05-26 FY27 guide of 16–17% growth triggered a ~31.5% single-day drop. ARR still +25% YoY to $3,525M; the recovery leg has carried price to RSI 67.8 at $168.68…

Oral STAT6 degrader (KT-621) re-rated on early BROADEN2 enrollment (6/25) and the $10.9B AbbVie–Apogee read-through, but the analyst upgrade cycle topped with RBC's 7/13 downgrade to neutral and the binary topline is 2H-2026 — a maturing,…

Two of three lead binaries (SPY001, SPY002 anti-TL1A) printed potential best-in-class; the stock absorbed a ~$399.7M director-fund block sale and sits back near its ~$102 ATH (~$95). Next legs — SPY003 IL-23 Part A (guided mid-2026,…

Second-leg breakout failed: after tagging a 52-week high $8.44 in early July, ABCL round-tripped to $5.31 (2026-07-24, -6.35%), losing the $6.79 shelf and $6.20 retest line, back at the June ~$5.09 base. The momentum edge is gone; what's…

VOICE outcomes win (USRC trial stopped early, June 2026) de-risked Vafseo's dialysis-anemia case, but the tape bled to ~$1.22, only ~48% above the $0.82 low and still fading; the late-July/early-August Q2 print is the binary —…

Coverage-and-flow leg has crested: -25% from the 2026-06-30 all-time closing high of $32.23 to $24.13 on 2026-08-07, no new sell-side action since JPM's 2026-07-14 maintain at $33, and three insiders selling in July's post-lock-up window.…

Best-in-class oral TYK2 story sitting near 52-week highs (~$28) as the market waits on the Q3 2026 LUMUS Phase 2b lupus topline — the binary that either re-rates envudeucitinib into a multi-billion indication or caps it as a psoriasis-only…

The July 14–17 Delaware bench trial closed with no verdict and no buyout; the quick-resolution crowd unwound and ANAB round-tripped from the low-$70s to ~$54 (Jul 24). The whole equity is now a dateless wait on a Chancery post-trial…

Precision-psychiatry re-rate (~10x off $2.85) re-armed on 2026-07-13 — a successful FDA meeting cleared an additional ALTO-207 monotherapy Phase 3 in TRD, funded same-day by a $100M raise at $26.48. Narrative refreshed, but every data…

Self-help turnaround at a leveraged lab-supply distributor is being repriced: the 2026-07-29 Q2 print put VWR Distribution & Services back to +1.7% organic from -4.8% in Q1, and FY2026 organic guidance was raised to -0.5%/+0.5%. Price…

De-rate reversal off the $7.48 Nov-CRL low has stalled near $14 after peaking ~$16 in early July; the opakalim epilepsy pivotal (RISE3) topline is unscheduled 2H-26, sell-side is turning cautious (BofA Underperform $11), and a dilution…

Statin-for-inflammation leg broke on someone else's Phase 3: Novo's ZEUS missed MACE at HR 0.99 on 2026-07-31 despite lowering hsCRP, and BIOA fell 59.6% intraday. QUELL-CV's primary endpoint is hsCRP — the exact surrogate ZEUS just…

The 2026-08-04 Q3 print resolved the binary against the margin case: adjusted EBITDA margin 13.7% vs the ~16% guide, and FY26 EBITDA cut to $275–295M from $315–335M even as the sales guide rose. Demand held, profitability did not. Price…

CAN-2409 lung program promoted to pivotal on the 2026-06-30 AURORA Phase 3 launch, and sell-side keeps stacking (Stifel Buy $22 on 7/13, avg PT ~$20 vs high-single-digit spot) — but the June breakout to $11.36 round-tripped to ~$9.50 and…

Analyst-confirmed profitability inflection (Q1'26 adj-EBITDA +$4.0M, +24% product rev) in a 25-year blood-safety grinder, but the 2.7x off the lows is largely spent and price sits near 52-week highs (~$3.00). The 2026-07-30 Q2 print is now…

Terminal special situation, unchanged: Lilly's $38.00 cash plus up-to-$9.00 non-transferable CVR scheme became effective 2026-06-24, last Nasdaq print was 2026-06-23, and Form 15-12G is dated 2026-07-06. The only live development is…

Deal-arb thesis is now spent: the $100M Apotex asset sale closed 2026-07-01 after a 99.84% shareholder vote on 2026-06-24, so the dated binary that drove the ~3.2x off $1.85 to a $7.36 high is consumed. What remains is a cash-rich clinical…

Elliott-driven turnaround at a beaten-down CRO: a ~$295M cost program plus 120–150bps margin expansion is re-rating the stock even with organic revenue still negative (-1.5% Q1), while Q1 proposals up high-single-digits YoY hint DSA…

The 2026-08-06 Q2 update pushed the registrational PTCL interim from late 2026 to a Q1 2027 futility analysis that publishes no efficacy data, and set AD Phase 2 topline at Q3 2027 — the binary clock this name traded on is now empty until…

Census-recovery re-rate broke at the 2026-08-04 Q2 print: EPS beat ($4.02 vs $3.88) but FY26 EPS was only affirmed at a $14.65 midpoint vs $14.82 consensus, with H2 revenue-per-treatment guided slightly negative. Price -23.7% from the…

CGM leader's recovery has aged from catalyst-pop to an analyst-revision grind — Mizuho $90 (7/15), Truist $87 (7/16) into a ~7% two-day pop to $76.65 — but price is high-$70s still under the 200-EMA and the confirmed July 30 Q2 print is…

Post-collapse deleveraging read: Q3 FY26 (2026-08-07) beat at $271.7M revenue and $0.56 adj EPS vs $0.27, and the FY26 adj EPS guide went to $1.80–$1.90 — three months after a 57.8% one-day break on 2026-05-05. The leg being bought is a…

Resolved and off the tape: ARCHIMED closed its take-private of Esperion on 2026-07-13 at $3.16 cash plus a non-tradeable CVR of up to $100M aggregate, and the common stock ceased trading and delisted the same day. Last listed close was…

ZEUS (ziltivekimab, MACE HR 0.99) failed on 2026-07-31 and took GLUE −27.16% to $16.52, its worst session on record, because the hsCRP-to-outcomes link under MRT-8102's ASCVD story is exactly what ZEUS could not demonstrate. Platform,…

GLP-1 reaccel gets marked to market on 2026-08-10: guide $680-700M (+25-28%) vs Q1's +4%, street at $698.9M. Since the last note the FTC/CA/UT sued (2026-07-29, N.D. Cal.), BofA cut $37 to $30, and Amazon ($50/mo Medicare GLP-1,…

Commercial ophthalmology special situation trading on one number: whether the guided Q2 ramp ($71–81M vs $44.2M Q1) prints ~2026-08-11. A ~40% recovery off the May low into ASRS clinical data and a fresh BTIG $63 reiteration has front-run…

M&A leg is dead — no SiriusXM headline since the 2026-05-29 NYT "stalled" report and the April spike fully round-tripped ($6.33 high → $3.86 on 2026-08-07, -39%). What is left is a binary: Q2 print 2026-08-10 after the close is the first…

Dilution overhang answered with debt: the 2026-07-16 Oxford amendment lifted the facility to $500.0M and funded $100.0M immediately, leaving the ~14.67M share count intact but the balance sheet levered into a nine-month wait for the…

Special-situation biotech, not momentum: the 2026 Linzess pricing-restructure re-rate faded to the low-$3s, then bounced ~30% to a $4.65 close July 8 on M&A speculation with no confirmed bid, since fading to ~$4.21. The Aug 6 Q2 print is…

Both binaries this stock coiled around have fired and are spent: JADE101's clean Phase 1 (2026-06-01, ~70% IgA reduction, q12w dosing) and Vera's TRUTAKNA accelerated approval (2026-07-07), which validated the APRIL/BAFF mechanism but put…

Closed takeout, not a security: Chiesi's $27.00/share all-cash acquisition of KalVista completed 2026-06-11, shares delisted from Nasdaq with deregistration (POS AM, Form 25, Form 15) underway. No spread, no momentum leg, no listed share…

ABC-platform redemption arc: after the 2022 DAZZLE wet-AMD miss took KOD to $4.60, back-to-back positive Phase 3 diabetic-retinopathy readouts (GLOW1, GLOW2) re-rated it ~9x. The September 2026 DAYBREAK wet-AMD topline is the binary —…

Pension-reversion fat pitch fired and is spent; the re-rate has fully unwound from the $14.87 May high to ~$7.78, losing the $9 June shelf and printing a $4.94 52-week low. A July 1 resale shelf of up to ~39.46M shares and a June 29 Sell…

In-vivo CAR-T re-rate has matured into digestion: EHA (6/13) confirmed LB2501's 100% ORR and clean durability, but the 6/17 $226M raise at $29.35 capped the leg and JPM's 7/13 Neutral $35 reinstatement caps the Street. No fresh catalyst…

APOL1 kidney precision-medicine story with clinical proof-of-concept in hand (Mar-25 HORIZON: 35.6% proteinuria cut, 61.8% in FSGS), but the tape has rolled over — $27.68, down 26% YTD and ~48% off the 52-wk high, no hard binary until…

The Aug 5 PDUFA resolved as an approval — mFLUSIVA is the first mRNA flu vaccine — and the tape did not break out: $59.17 on 2026-08-07, 27.7% under the 52-week high. Moderna guided to no meaningful 2026-27 season revenue, so the flu leg…

Post-COVID survivor re-rate has run its momentum leg and is now digesting a parabolic +31% push to a fresh 52-week high of $6.22 (June 26). Every driving catalyst is public, the move is idiosyncratic with no life-science-tools cluster…

Legacy hereditary-cancer testing house executing a diagnostics pivot; shares +40% off the June $3.99 base as Prolaris+AI launched (May 26) and Precise MRD colorectal/renal was pulled forward to Q3. Structure has repaired but now…

Oncology-dx turnaround ACCELERATING — NGS +26%, PTEN IHC CDx (first FDA IHC companion dx in prostate, paired to AZ's TRUQAP) launched Jul 9, and TD Cowen $14→$19 / BofA $11→$16 on Jul 13 lifted consensus to ~$15.67, back above spot. But Q2…

GSK's $124/share all-cash acquisition has closed: the tender expired 2026-07-14 with ~91.3% of shares tendered and accepted for payment, satisfying the minimum condition and triggering a Section 251(h) merger, Nasdaq delisting and SEC…

Growth-compounder narrative is dead: Q1 first orders -50%, revenue -26%, and the $9.25→~$17.88 summer bounce has bled back to $14.12. The Q2 print slipped from mid-August to 2026-09-09, leaving a month with no dated catalyst and price…

Takeover binary is resolved and deal-pinned: OGN trades ~$13.51 into Sun Pharma's $14.00 all-cash offer, a ~$0.49 (3.7%) gross spread. The 2026-07-06 disclosure suit was mooted by 2026-07-17 supplemental proxy filings, clearing the path to…

FDA's 2026-06-17 reversal put AMT-130 on an accelerated-approval path with a Q3 2026 BLA — the narrative is genuinely repaired, but the move is spent: $40.25 (7/17) sits below the $45.50 June offering price with the CEO selling into it on…

Oral-GPCR platform narrative has cooled from accelerating to maturing: a marginal new high at $38.04 (2026-07-11) failed and the tape faded ~13% to $33.10 by 2026-07-24 into a catalyst vacuum. The first real binary (SEP-479 Phase 1) isn't…

April denifanstat/acne breakout round-tripped to the $6.00 Series A offering floor; SGMT bases near $7 (last close $7.06, 2026-06-26) with no trend. Dermatology pivot (China NMPA acne NDA accepted Dec 2025, US IND due mid-2026) is real but…

A record short squeeze (~32% of float) and buyout speculation, now joined by sell-side PT hikes (Alliance Global $10→$25, Jul 17), have carried SLS to a $16 test and back to ~$13; the defining Phase 3 REGAL overall-survival readout stays…

Single-asset ivonescimab binary sitting $1.26 above its $12.55 52-week low with going-concern language on the record. The narrative leg is dead but the funding question changed shape: co-CEO Duggan bought 3.81M shares at $13.12 on Jun 12…

Single-product epinephrine name whose one catalyst — a July no-prior-auth formulary add for neffy — came and went unpaid; the stock has since broken its old $6.66 52-week low to fresh lows near $6. The neffy ramp is real but the access…

Single-asset binary now inside its own catalyst window: the STRO-004 (DAR8 Tissue Factor exatecan ADC) Phase 1 readout was guided "mid-2026" and that window is expiring undated. Price has gone flat at ~$29.7 for four weeks after the June…

Fallen-angel telehealth turnaround re-rating off lows: TDOC doubled from its $4.40 low to a fresh $9.78 52-week high on the Walmart Better Care distribution deal and BetterHelp's shift to insurance-reimbursed visits. But total revenue…

Closed merger-arb: shares pinned just under Merck KGaA's $73 all-cash bid (06-25, $11.3B EV, expected close late-2026/early-2027). The full sell-side has folded targets to $73 (RBC 07-09 the latest). No narrative leg left — only thin…

Clinical binary printed clean (2026-06-22: 100% milestone response N=12, zero treatment-related SAEs) but the next catalyst slipped to H1 2027 — pivotal six-month interim AND FDA BLA-pathway feedback both guided to the first half of next…

FILSPARI's dual-indication ramp has fully re-rated the equity: at ~$56.71 (2026-07-17) TVTX trades at consensus PT ($52–58) and 4% under its 2026-06-25 ATH close of $59.03, having gone sideways for four weeks. The approval binary is spent;…

The Novo squeeze is fully round-tripped and the funding answer arrived on 2026-07-02: a $21.8M at-the-market program via Oppenheimer/Canaccord. At $2.42 (07-15) that is ~9M shares against ~16M outstanding — the company will now sell stock…

June's volume-backed reclaim to $10.03 failed to extend — $9.43 on Jul 17, -5.3% on the week, with short interest rising to 11.72% of float as shorts pressed the fade. Structure holds above the 50-DMA near $8.71, but nothing hard is dated…

Last large independent GLP-1/GIP obesity asset and a live M&A target, but VANQUISH pivotal topline is a 2027 event — a catalyst vacuum bridged only by a 3Q26 maintenance-dose readout. Tape rolling over from ~$40 (07-09) to ~$35.50 (07-25),…

Busted-growth genomics name; the recovery off the −49% May guide-cut crash has stalled in the low-$60s, below the $74.83 200-day. The confirmed Aug 3 Q2 print (blended ARR vs the ~$3,300 baseline) is the binary — the same day as the…

Two analyst target cuts in ten days (Wells Fargo to $170, DA Davidson to $200) into the 2026-07-29 Q2 print signal de-risking ahead of the H2 comp-turn binary; a ~50% relief bounce off the $116.35 low is unproven, and the print — not…

Post-X-TOLE2 de-risking (2026-03-09, placebo-adjusted -42.7%, p≈6e-12) already re-rated azetukalner from the $40s to new all-time-high closes near $71. The story is now maturing into a procedural Q3 2026 NDA, with the next true binary…

Delisting binary fully resolved to the survive side — Nasdaq confirmed regained compliance 2026-07-20, but with a one-year no-cure monitor attached. What's left is a ~$7M psilocybin micro-cap with a going-concern warning and heavy…

Both Phase 2 trials (TibuSHIELD/HS, TibuSURE/SSc) are now fully enrolled and fresh William Blair + Chardan bull notes landed in early July, but the enrollment-momentum leg has stalled — 2026-07-17 volume ran ~82% below average and price is…

The June patent re-rating fully reversed: EMA's CHMP issued a negative opinion on arimoclomol's EU application 2026-07-24 (efficacy not proven), and ZVRA gapped ~24% to the high-$9s, cutting through the $11.50 base. EU expansion is now…

Conway extract/RTD/flavors platform inflecting capex-to-cash: Q1 (5/07) beat + record adj EBITDA + FCF-positive-H2 guide; the 6/30 debt-maturity extension cleared the refi wall. Stock re-rated to ~$9.50 near the $9.81 52-wk high. Q2…

The +80%-off-March recovery re-rate has matured and rolled over: Morgan Stanley pulled its Overweight ('valuation call') on 2026-06-25, and price faded ~30% from the $100 high back onto the reclaimed 200-day near $70 while targets stayed…

Self-help turnaround at a leveraged lab-supply distributor is being repriced: the 2026-07-29 Q2 print put VWR Distribution & Services back to +1.7% organic from -4.8% in Q1, and FY2026 organic guidance was raised to -0.5%/+0.5%. Price…

Lemonis "Everything Home" roll-up keeps closing deals — Container Store now wholly owned (2026-07-08), TwoPonds folded in (2026-07-01) — but the tape has bled from $5.83 to ~$4.96 and sits on the $4.26 52-week low as shares balloon past…

Rotation-passenger thesis is dead and the self-help turnaround hasn't ignited: BBWI made fresh relative lows near $19 into the 2026-07-12 Ulta launch, down ~42% over 12 months and below its 200-DMA while the tape holds up. Goldman cut to…

Tape flipped since early July: BBY broke to a fresh 52-week high $87.35 (~$85.41 on 2026-07-17, +27.6% YTD) on RGB-LED TV exclusivity plus an AI-PC/MacBook refresh cycle. But price sits ~8% above the $79.15 consensus target while Loop…

The premium-to-book re-rating has unwound: BH ~$384 (Jul 17) sits back under the ~$401/Class B book line while CBRL rallied to $53.61 — the holdco is falling as its main asset rises, re-widening the discount. A $500M ATM with ~$485M…

Post-miss +46% V-recovery has rolled over — ~$44 from a ~$48.75 June high, never retesting the $53.53 ATH. The tell: fresh $500M buyback authority funded by the June 19 €900M notes landed and the stock still faded. S&P cut the outlook to…

Casual-dining margin-repair story re-rated violently on the 2026-08-05 Q2 print (adj EPS $0.39 vs $0.29, FY26 adj EPS guide lifted to $0.90–$1.00). The narrative is three days old and already gave back from $12.29 intraday to a $10.95…

The 2026-08-04 Q3 print resolved the binary against the margin case: adjusted EBITDA margin 13.7% vs the ~16% guide, and FY26 EBITDA cut to $275–295M from $315–335M even as the sales guide rose. Demand held, profitability did not. Price…

Drive-thru coffee comps re-accelerating (Q1 +8.3%, FY guide raised) and the sell-side is now catching up — Stephens initiated Overweight $80, Morgan Stanley to $88 in mid-July. But June's run to ~$72 cooled to the mid-$60s, and the…

Casual-dining re-rate got a genuine second leg: Citi's 2026-07-10 raise to a street-high $90 (Buy) on a rewards/app traffic-inflection thesis gapped shares 7% to all-time highs (~$86, 52wk high $86.66 on 2026-07-18). For the first time the…

Q1 re-rate is spent and the tape has gone flat — CAL has chopped a tight $11–$12.6 band near $11.78 (2026-07-24), ~19% below its pre-print level and under the lost low-$13s June shelf. Slow brand-mix-shift value name, not an accelerating…

Legacy-diner turnaround has handed off from numbers to leadership: David Deno (ex-Bloomin' Brands CEO) takes over 2026-08-10 with shares roughly doubled YTD and the 2026-08-07 close of $57.79 above every published target except Argus's…

Sell-side cluster finally formed — Citi Buy/$45 and Mizuho Outperform raised to $41 (both 2026-07-13) joining JPM's Overweight, plus first Mexico restaurant announced — but the ~2026-07-22 Q2 print is three days out and no weekly 20-EMA…

Q2 FY26 (2026-07-23) beat on every line — net sales $216.2M +28.1%, EPS $0.82 vs ~$0.55, FY guide raised to $790–805M — and the stock still closed $62.25 on 2026-08-07, -25.9% from the post-print high. Beat-and-raise absorbed by sellers;…

Fee-reform catalyst landed: the 2026-07-13 Ninth Amended MSA cuts the base fee from 2.00% to 1.25% of ANA and caps 2027 base fees at $30M (est. $19–22M saving) — but nothing hits P&L before 2027-01-01. Price recovered ~$10.08 (2026-07-08)…

Distressed, highly-levered beauty turnaround (net debt ~$3.17B, ~3.3-3.4x) bouncing +23% off its ~$1.82 all-time low on the ~$400M Gucci license transition to Kering and cost-out. A de-lever story, but the ~Aug-19 Q4 print is the binary…

Hardware-to-platform crossover: Q2 2026 Platform revenue $85.0M (+5%) now exceeds Products $71.3M (-22%), and shares gapped +22.9% on 2026-08-05. The fuel was non-recurring — $20.3M IEEPA tariff refunds plus a $6.4M reserve release; the…

Turnaround re-rating still catching fresh fuel: analyst targets cluster up to $160 (BofA 2026-07-23, Seaport 2026-07-20) on North America DTC re-inflecting, lifting CROX to ~$135 within 4% of its all-time high at ~10x forward. Revenue is…

Margin-inflection leg: Q2 FY26 (2026-08-06) delivered adj EPS $0.23 vs $0.07 consensus, a record 33.2% gross margin and an FY26 EPS guide of $0.85–$0.94 vs $0.72 est. Price closed 2026-08-07 at $14.35, the 52-week high and above three of…

Value-apparel turnaround is fundamentally accelerating — Q1 FY2026 comps +13.9%, a 21-month positive streak, a raised FY guide — but the 2026-06-02 print was the catalyst and it fired ~7-8 weeks ago. On an ~8.1M float with 10.5% short…

Deleveraging-and-refranchising turnaround with a now-dated catalyst: Q2 FY2026 prints 2026-08-06. Net leverage cut to ~5.5x from 6.7x, liquidity >$300M, but revenue still shrinks and ~23-29% of the float is short. The tradeable energy is a…

Take-private special situation: the board rejected Yellow Wood's $30 bid as too low, and mid-July sell-side PT raises (Canaccord $34, Wells Fargo $30) confirm a >$30 intrinsic read. But a month on no competing bid has surfaced, the theme…

Legacy watch/accessories brand whose margin-first turnaround is showing in the numbers: Q1 2026 swung to $12.0M operating income from a $(6.7)M loss on net sales of $224.8M, and the FY2026 guide (-4% to -6% sales, 3-5% adjusted operating…

Payments roll-up at ~$50, a hair above its $46.26 52-week low set on a 2026 guide-down. The Global Blue tax-free-shopping integration ("Shift4 One," launched 2026-07-14) is the transformation leg, but the 2026-07-30 Q2 print is the binary…

Busted-merger workout losing its bid: the +48% June bounce to $14.87 (on a speculative Amazon-bolt-on thesis) has faded ~13% to ~$13, whole-company sale is now reported "unlikely," and the 2026-07-10 chairman exit forfeited…

Take-private arb in its endgame: DEFM14A filed 2026-07-06, vote 2026-08-03, HSR expired 2026-06-22. Closed $9.44 on 2026-07-31 vs the $9.50 cash price — ~0.6% gross left against a ~37% break tail to the unaffected $5.93. Only offshore…

The operating turnaround is real but priced, and its one asymmetric leg — the activist proxy fight — lost its teeth: ISS (2026-07-07) backed all nine board directors and urged holders to withhold from the two Radoff/Jumana nominees, so the…

Premium-golf consumable franchise (Titleist Pro V1) that ran to a $119.65 all-time high on a defensive-quality rotation, then bled ~11% of the mania premium back to the ~$104–105 June breakout shelf ($104.66 on 2026-07-24). The 2026-08-06…

AI-native restructuring re-rate — up to 400 job cuts, FY26 EBITDA guide raised to $75–80M — plus a low-float, Russell-inclusion squeeze that popped GRPN +10% on 2026-07-16. But Q1 billings fell 1% YoY and sell-side sits at Sell: a maturing…

The 2026-07-08 double beat was sold — closed $25.18, -10.2% — because margins compressed (GM 46.0%, -110bp; adj EPS $0.17 vs $0.41). The live leg is now deleveraging: net leverage 3.48x from 3.87x, debt $716.1M from $871.0M, FY27 FCF…

Margin re-rate, three days old: Q2 gross margin 48.4% (+800bps) and a four-way FY2026 guidance raise on 2026-08-05 drove a ~39% single-session repricing. Price at $5.46 is a 52-week high, RSI 83.3, and above both $5 targets raised in…

Post-sanctions PACE turnaround still delivering (FY2026 adj-EBITDA guide $85–90M, census ~8,050 +6.9% YoY), but the tape shifted: a $12.11 52-wk high failed back into range ($11.18 close 2026-08-07), and the 2026-07-31 S-3 registered…

Quality-defensive re-rating (~+39% YTD, ~$122) is maturing: Q2 net sales grew just 2% to $341M with anchor license Lacoste -19%, yet Canaccord chased its target to $141 (2026-07-23) as sell-side catches up to decelerating growth. Full Q2…

June's move was a float mechanic — Russell Microcap inclusion (effective 2026-06-30) into a 40%-short float drove $8.92 to $18.13, and it is unwinding ($14.98 on 2026-07-17, -7.76%). SSS is genuinely inflecting (-6.7% → -3.8%), but price…

Genuine FY2026 turnaround (loss→$3.6M net, record $166M rev) plus a +20–22% Q1 guide drove a +36% circuit-breaker gap on 2026-06-15. Six weeks on the catalyst is spent, the only new item is a 2026-07-21 board-chair succession, and RSI-88.6…

Squeeze leg has stalled: Morgan Stanley's 2026-07-06 Underweight/$15 reinit broke the one-way upgrade cluster and knocked the stock -5.9% on 07-08. Price ~$17.18 still holds above the 50- and 200-day, but with the sell-side now two-sided…

Q1 FY27 (2026-06-11) beat in a shrinking furniture category, but the tape refused the news and no volume-confirmed reclaim has fired five weeks on. With ~27–31% short float and clustered June insider buys, the only live edge is a squeeze…

Morgan Stanley broke the all-Hold wall on 2026-07-06, resuming at Overweight with a $30 target and a $3 EPS-power call vs ~$2 consensus — the first real upgrade catalyst since the Q1 beat. But price faded the note ($23.99 → $22.64 by…

Deli prepared-foods roll-up keeps compounding — Q1 FY2027 (2026-06-08) revenue +49.7% YoY — but management top-ticked the 52-week high with a $100M raise at $18.00 (2026-06-30): ~14% dilution, momentum reset, theme cooling to maturing. No…

Take-private process went live: WSJ reported substantive Diller talks 2026-07-10, MGM seated a special committee mid-July, and the board reportedly views $48.30 as too low — so the trade is now a bump handicap, not a growth story. At…

MakeMyTrip's mid-year recovery bounce has stalled: after reclaiming the 200-day near $55, MMYT rolled back to ~$49, below both the 50- and 200-day, straight into an August 3 Q1 FY2027 print where consensus models EPS down ~76% YoY on ~137x…

Margin-led re-rate (Q1 FY27 GM 57.3%, +320bp; adj EPS $0.32 vs $0.08 est) is already priced at $38.65, ~3% off the $39.85 high after six weeks of chop. The live variable is the 2026-07-24 Section 122 expiry: the 10% Swiss-watch surcharge…

Housing-rebound-on-rate-cuts trade that carried MTH to a $85.38 52-week high has reversed: it lost the $75 June breakout shelf to $74.17 (-4.2% on 7/17) as mortgages held at 6.49% and Zelman capitulated to Neutral (7/7). Fundamentals still…

The June oil-tailwind cruise re-rating has matured and rolled over: July downgrades (Truist. Narrative velocity has reversed; the highest-beta name gives it back fastest.

Post-capitulation base off the $41.35 low is holding, but the estimate-revision direction has not turned. The 2026-07-22 decision to sever China distribution (Topsports online terminated 2027-01-01) deepens the near-term China reset even…

Mid-July analyst cluster — JPM & Barclays Overweight PT $7, UBS Neutral PT $4.75 — has sell-side validating the Chris Peterson turnaround, and the tape pushed higher into 7/22. But a binary Q2 print lands before open 7/31, gating a full…

Growth-compounder narrative is dead: Q1 first orders -50%, revenue -26%, and the $9.25→~$17.88 summer bounce has bled back to $14.12. The Q2 print slipped from mid-August to 2026-09-09, leaving a month with no dated catalyst and price…

Closed by event: the Henkel all-cash takeout completed and OLPX was delisted from Nasdaq on 2026-07-07, with each share converted into the right to receive $2.06 cash. There is no longer a listed security, no price series, and no thesis to…

Oatly doubled its FY2026 constant-currency revenue growth guide to 8–10% from 3–5% on 2026-07-22 and printed positive adjusted EBITDA (+$0.4M). The re-rating leg is roughly two weeks old, RSI is 71, and no company catalyst is scheduled…

Recovery leg re-fired: $66.06 (2026-06-05) → $71.49 on 2026-07-15 (+5.9%) → $73.20, back within 3% of the $75.25 high and ~6% ABOVE the $68.80 consensus target. Wells Fargo's 2026-07-10 note flags June financing data accelerating into a Q2…

Failed turnaround grinding at 52-week lows — $9.87 close, sitting on the $9.40 low. The 2026-06-15 binary resolved bearishly (comps -5.4%, EPS $0.16 vs ~$0.60 consensus) and the June squeeze fully round-tripped. No momentum, no catalyst…

Special-situation setup: an April-2026 strategic review (Morgan Stanley engaged) puts a possible sale on a controlled, down-~90%-from-IPO name, while record DTC revenue (+62.8% YoY) and Disney Solitaire drove a Q1 guidance raise. The Aug 6…

Post-Russell momentum squeeze in a recent-IPO e-commerce compounder has broken — down ~25% from the $29.80 high to $22 in four sessions on a macro tech rout plus a Bear Cave short report. Fundamentals intact (raised FY guide, 127% NRR) but…

Post-print wreckage, not a turn. FY26 EPS held only via a ~$100M one-time tariff refund while the revenue guide went flat (2026-06-03, −25% overnight); BofA capitulated to Underperform/$70 on ~50% EMEA exposure (2026-06-25). The bounce to…

Broken growth compounder: the age-verification rollout throttled DAUs and forced FY26 bookings guidance down to +8-12%; stock is -66% from its $150 high and below the 200-day. The 2026-07-30 Q2 print is the binary — it needs a DAU…

Luxury-resale turnaround has reached a durable adjusted-EBITDA inflection — FY2025 positive EBITDA all four quarters, Q1 2026 GMV +24%, FY guide raised — but the re-rate off ~$5 is largely spent and the tape is range-bound near $11.4. The…

Consumer-discretionary rotation lifted a heavily-shorted luxury home-furnishings name; Goldman's Neutral upgrade (PT $155, 2026-07-08) marks the squeeze going public as CEO Friedman sold 125,000 shares into the pop — a maturing rotation,…

June's +20% deleveraging bounce has fully round-tripped: $1.99 (6/26) back to $1.73 (7/17), now under the 50-day near $1.79 after failing exactly at the $1.99 consensus PT. Balance sheet is fixed, narrative is not accelerating, and a…

GPU-normalization narrative broke at the 2026-07-30 print: revenue and adjusted EPS beat consensus, but adjusted EPS fell 17% YoY, franchised segment income −23%, and EchoPark FY26 GPU guidance was cut ~$300 at the midpoint. Shares…

Online-styling turnaround printed a 5th straight growth quarter and first sequential client gain (Q3, 2026-06-10) with a raised FY guide, but the post-print pop has fully round-tripped to ~$3.58 (2026-07-24) onto the $3.50 shelf, a second…

Cyclospora outbreak crushed SG from ~$9 to $6.15 (Jul 16) on guilt by association; FDA traceback cleared it Jul 17 (source: Taylor Farms iceberg at Taco Bell), sparking an 18% bounce to ~$7.08. Now below the $7.92–$8.43 consensus with…

Tariff-recovery leg has stalled into a $39.71–$47.11 range with insiders selling every rally and zero buys; the whole story now hinges on the confirmed 2026-07-30 Q2 print. Consensus targets sit at or below spot ($43.75, 07-16), adjusted…

June's busted-IPO recovery leg has fully reversed. D.C.'s RESALE Act (10% resale-markup cap, effective 2027-01-01) plus a Texas AG probe into undelivered World Cup tickets broke the experience-economy narrative; at ~$8.60 STUB trades below…

Busted-IPO thrift retailer's June recovery has stalled and rolled back toward its ~$9 base as the June 27 Russell-deletion passive-bid loss bites; the July 30 Q2 print is now an imminent, FX-exposed binary rather than a five-weeks-away…

Tariff/de-minimis "secondhand wins" re-rate has matured into dead money: TDUP slid from ~$7 to $5.70, lost its ~$5.90 recovery shelf and sits on the Street-low price target while sell-side keeps trimming. The Aug 5 Q2 print is the binary…

M&A event fully fired: Intersnack's $14.25/share all-cash take-private (announced 2026-07-21) gapped UTZ ~90% and pinned it at the offer. No momentum leg remains — only a thin, capped merger-arb spread to close, which is not this book's…

New-management turnaround re-rating has stalled: after Goldman's June double-upgrade drove VAC to a $105.97 high, price rolled ~11% to the low-$90s while the two most recent Street notes (Morgan Stanley $52, Wells Fargo $68) are both…

Q1 blowoff (+47% on 2026-06-02, adj EPS $0.60 vs $0.32) already re-rated the equity to a $88.57 high before fading to the mid-$70s. Activist overhang cleared, sell-side no longer leading price, no dated catalyst until the ~late-Aug Q2…

Margin-inflection turnaround has stalled: after the June Evercore-driven pop, W has faded ~10% back to the ~$84–85 recovery base ahead of the binary Aug 4 Q2 print. Wedbush's Jul 16 Neutral/$104 initiation and a ~$100-capped consensus mark…

Two analyst target cuts in ten days (Wells Fargo to $170, DA Davidson to $200) into the 2026-07-29 Q2 print signal de-risking ahead of the H2 comp-turn binary; a ~50% relief bounce off the $116.35 low is unproven, and the print — not…

Quality home-furnishings compounder in the consumer-discretionary rotation; Q1 (2026-05-21) reaccelerated every brand to positive comp and the revision cluster keeps building (KeyBanc raised to $250 on 07-07). At ~$226.74, ~7% under the…

Digital-MSK profitability re-rate broke out in May and was pushed into open price discovery by the 2026-06-09 mid-quarter raise (Q2 to $200–202M, +45%; FY26 to $818–824M). But nine sell-side target hikes in two weeks plus accelerating…

The 2026-08-04 breakout above the July band failed within three sessions — SNX closed $252.42 on 2026-08-07, back inside the $235.67–$255.70 range and under the 50-day. The move up came on Arista's print, not company news; Hyve's +117%…

Record-revenue franchise priced for terminal AI disruption: closed 2026-07-31 at $250.41, ~9.6x NTM earnings vs Microsoft 23.1x, 31% below the 52-week high, with a $25B buyback running. The bear narrative is fully mainstream and nothing…

De-rated design-software compounder: Q1 FY27 revenue +18% to $1.934B and current RPO +18%, against a stock 23.8% under its $326.79 high. The $3.6B MaintainX close (2026-08-03) extends the franchise from CAD seats into asset operations; the…

Hospitality vertical-SaaS recovery has re-accelerated into its print: AGYS ran ~+18% to $108.98 (2026-07-10) off the June ~$92 base, clearing the two lowest analyst targets ($100/$110) ahead of a confirmed 2026-07-27 Q1 FY2027 binary that…

AI-agent-security theme is accelerating, but AKAM's July 8 re-firing (+8–10% toward $126) has fully faded to ~$115, rolling back toward the June lows — a legacy-CDN-to-security/compute pivot that is NOT confirming the theme's momentum. The…

Q1 FY27 gave the pivot real numbers (QNX $72.3M vs the $60-64M guide, FY27 raised to $594-621M), but the parabola broke: after a $13.59 high the stock fell ~37% to ~$8.54 on a meme unwind plus insider selling. Narrative maturing, price…

Busted vertical-SaaS name re-rating on cash return: the 2026-07-29 Q2 print showed +3.0% organic and an affirmed FY26 guide with upper-half commentary, against ~$850M of remaining buyback authorization and an 8.16 forward P/E. The move is…

Second-order AI-server reseller whose ~37% recovery off the $97 low has stalled: a mid-July push to $144 round-tripped to $133 by 2026-07-17, right in the fairway of the ~$145 consensus target. The re-rate (JPM, MS $170, Citi $145) is…

Takeover-premium leg is dead: the 2026-07-06 Vista/Quinti gap is fully filled and the 2026-08-05 print cut FY26 contribution ex-TAC guidance to $1.034–1.058B from $1.175–1.198B, re-basing the standalone any bid would price. No board…

Legacy-networker AI re-rate intact and now at its binary: the $118–120 shelf held through July, price closed $121.43 on 2026-08-07 with RSI(14) at 78.4, and five sell-side target raises landed 07-22 → 08-06 (Citi $112→$139) ahead of the Q4…

Legacy IT-services name being re-underwritten as an enterprise-AI deployment partner: 2026-07-29 Q2 lifted FY26 adj EPS guidance to $5.70–$5.82 and expanded margin 40bps while cutting the FY revenue band to $22.04–$22.35B. The re-rating is…

June's sell-side upgrade wave has exhausted and the first cut printed — Bernstein to Market Perform (PT $226, 2026-07-06) as the stock rolled over. AI-observability narrative intact but maturing; the $278.71 parabola round-tripped and the…

Fusion pivot is the leg: the 2025-12-18 all-stock TAE Technologies merger (>$6B, ~50/50 fully diluted) is what's actually being bought, while the crypto-treasury leg was terminated 2026-08-07. The S-4 was still unfiled as of 2026-08-05,…

Fundamentals accelerated on the 2026-08-04 Q2 print (revenue +29% YoY, AI ARR +212%, RPO $894M, FY guide raised) and the stock fell 10.9% anyway. The $132 shelf flagged in the July coverage broke; the 2026-08-07 close is $124.15, -31.5%…

Legacy e-signature base being re-wrapped as AI "Intelligent Agreement Management" — IAM went 10.8%→12.6% of ARR in one quarter and is guided to ~18% by 2027-01-31, but total growth is still ~9%. Price has recovered to roughly the consensus…

Legacy IT-services decliner being re-rated as an AI-centric pivot: AI-framed leadership change 2026-07-30, ElevenLabs and Primary partnerships inside ten days, FY27 non-GAAP EPS guide of $2.40–$2.90 affirmed against a $10.84 close.…

Smadex AI-DSP re-rate broke to a new 52-week high of $13.48 with no dated company news since 2026-07-12 — an anticipatory leg into the 2026-08-10 Q2 print, the binary on whether Q1's +204% ATS growth and ~22% EBIT margin held.…

Legacy expense-SaaS pivot re-rated on the 2026-08-06 Q2 print: revenue $33.9M beat $33.688M, paid-member decline halved to -2% YoY, FY26 FCF guide doubled to $12M-$14M, ~7% of shares retired, and New Expensify ARR from net-new customers…

Legacy campus-networking name re-rating ~+140% off Feb lows on the Platform ONE / Agent ONE AI-NetOps story plus SaaS ARR +29% YoY; theme still ACCELERATING but spot ($33.71, 07-10) has run through consensus PT $29.06 into the June bull…

Design incumbent re-rated as an AI winner (BofA Buy, $30 PT, 7/7) rather than an AI casualty, yet the stock churns below its 100/200-day moving averages with heavy short interest into its first public earnings print on 8/5 — that print,…

Legacy-CCaaS AI pivot staged a sharp V-recovery: +29% off the $19.70 June swing low to $25.42, reclaiming the broken $22 shelf on a 2026-06-23 next-gen Voice AI Agents launch and an AI-first leadership overhaul. Now pressing the $26.26…

Agentic-operations pivot is compounding in the segment data — Advanced Technology Solutions +24.1% to $363M, FY guide raised to at least 25% on 2026-08-06 — but the 73% legacy book grew 1.9% and caps total growth near 7%. Shares fell ~3%…

June drawdown fully retraced — $23.01 close (2026-06-22) to $27.63 (2026-07-29), still short of the $27.76 shelf from 2026-06-01 — and it happened on no company news. The now-confirmed 2026-08-06 Q1 FY27 print is the first quarter with…

Legacy B2B data business attempting to re-rate as an AI go-to-market platform. Q2 (2026-08-05) beat and raised on 1.2% revenue growth, 89% NRR and a $650.5M goodwill impairment; the stock ran ~14% in two sessions to $4.18 (RSI 76.9), above…

Vertical-SaaS insurance compounder de-rated ~52% from its $272 high; the 2026-06-04 Q3 beat-and-raise (rev +27%, ARR $1.147B) was sold and price sits in a broken structure far below every analyst PT ($180–258). The enterprise-software AI…

No base, no scheduled company event before UNBOUND on 2026-09-16.

M&A leg is dead — no SiriusXM headline since the 2026-05-29 NYT "stalled" report and the April spike fully round-tripped ($6.33 high → $3.86 on 2026-08-07, -39%). What is left is a binary: Q2 print 2026-08-10 after the close is the first…

Agentic-AI attach on a compliance-locked professional-firm base: Celeste launched 2026-07-15, Q4 FY26 (2026-08-04) beat with cloud ARR $495.7M +29% and 123% NRR, three targets raised 2026-08-05. But the FY27 revenue guide $656.5–660.5M…

Klaviyo beat Q1 2026 (rev +28%) yet gapped -32% on a light FY26 guide (~$14–22M below consensus), a CFO exit, and visible deceleration (23% FY guide); shares sit near 52-week lows below the 200-day into a binary Aug 5 Q2 print.…

Contested insurtech IPO reclaimed its $19 price in a late-June ~28% rip and has held it into a fresh JPM Overweight (PT $23, 2026-07-13). But the reclaim runs into the 2026-07-27 final lock-up and an unresolved upfront-accounting short…

Atlas re-acceleration (+29.4% YoY, record $117M seq add; Q1 FY27, 2026-05-28) is intact, but the +18.5% post-print breakout fully round-tripped from $444.72 to a $294.10 close as the AI-software theme sold on margin-timing fear. Sell-side…

Agentic-ad-infra narrative (Magnite Orchestration + Walmart Connect commerce-media) matured from a June breakout into a low-$20s plateau; Wells Fargo's 2026-07-17 neutral PT-nudge to $21 shows sell-side catching up, and the binary…

The Aug 5 PDUFA resolved as an approval — mFLUSIVA is the first mRNA flu vaccine — and the tape did not break out: $59.17 on 2026-08-07, 27.7% under the 52-week high. Moderna guided to no meaningful 2026-27 season revenue, so the flu leg…

Recent IPO (Oct 2025, $25 price) running an AI-native travel-and-expense platform; growth reaccelerated to +34% YoY in Q1 FY27 with FY guide raised above consensus. But the tape cooled from $28.22 to ~$22 — the enterprise-AI-software theme…

The IPO re-rate leg already failed — price sits 36.7% under the $18.45 52-week high. What is left is a margin/deleveraging story: Q1 adjusted EBITDA margin 21.0% against a 23.5–23.8% FY26 guide, funded by $70–80M of restructuring savings.…

AI-networking legacy re-rate extending on a harder catalyst leg — first commercial AI-RAN platform with Nvidia (07-15) plus Taiwan Mobile, Orange Belgium and NestAI defense wins. Theme ACCELERATING, but the 2026-07-23 pre-open Q2 print is…

Genuine VAR margin-mix turnaround (Q1 GM +240bps, cloud GP +35%) but a derivative AI tag: hardware GP guided flat, sales +1%. Range-bound $102–123 since the early-June rejection; ~$110 already sits above the ~$103 street target with a…

FY27 guided as a reinvestment year: revenue $5.135–5.185B versus FY26 actual $5.246B, adj EBITDA margin 32–33% versus 36.3%, funding $100–200M of growth spend. The AI-data-foundation re-rating has not arrived; what remains is $807.5M FY26…

Beaten-down bill-pay compounder: Q1 2026 revenue +30.2% YoY yet shares carved a $20.11 June 52-week low on margin-mix fear. Now ~40% off that low into a binary ~Aug-4 Q2 print — the read is a recovering base, not a chase.

Automation-and-buyback operating-leverage story re-rating a de-rated HCM name: Q2 (2026-08-05) beat revenue $531.2M vs $513.1M and EPS $2.78 vs $2.38, FY26 guide lifted to $2.197–2.212B, nine targets raised 2026-08-06. Leg is fresh, but…

Ad-tech SSP growth-inflection re-rating: Q2 2026 revenue $78.6M, +11% YoY, first double-digit quarter after three declines, with a Q3 guide of $75–77M vs $71.1M consensus. The 2026-08-06 print repriced the stock to a 52-week high $17.78…

Merger-arb stub, not a momentum vehicle: the Publicis $38.50 all-cash deal now has a dated shareholder vote (2026-08-17, 66⅔% threshold) and HSR filed 2026-06-11. At ~$37.82 the remaining spread is ~1.8% into a year-end close, against…

Broken growth compounder: the age-verification rollout throttled DAUs and forced FY26 bookings guidance down to +8-12%; stock is -66% from its $150 high and below the 200-day. The 2026-07-30 Q2 print is the binary — it needs a DAU…

Beaten-down UCaaS name popped ~24% on a 2026-07-23 Q2 beat-and-raise plus an OpenAI-adoption headline. But sell-side stayed Neutral (PTs $40–43), and the AI pivot is thin — internal adoption plus a hackathon, no attached revenue. Buying a…

Ex-growth cyber name (Q1 2026 rev -0.3% YoY; Q2 ARR guided to ~$820M) trading near $11 purely on a Jana-forced take-private; Goldman/JPMorgan shopping RPD to Advent/Bain/EQT. Newest sell-side PTs now cluster $9–11 at the tape as deal…

June's +20% deleveraging bounce has fully round-tripped: $1.99 (6/26) back to $1.73 (7/17), now under the 50-day near $1.79 after failing exactly at the $1.99 consensus PT. Balance sheet is fixed, narrative is not accelerating, and a…

Oral-GPCR platform narrative has cooled from accelerating to maturing: a marginal new high at $38.04 (2026-07-11) failed and the tape faded ~13% to $33.10 by 2026-07-24 into a catalyst vacuum. The first real binary (SEP-479 Phase 1) isn't…